Medpace Holdings, Inc. (MEDP) President and CEO August J. Troendle reported share sales totaling $1,589,941 across two transactions, according to an SEC Form 4 summary published September 29, 2026. The supplied information identifies a September 28 sale of 2,410 shares at $620.07 each.

The summary states that the filing did not involve a Rule 10b5-1 trading plan. It provides only a partial transaction breakdown, so the identified share count and price should be distinguished from the aggregate dollar amount reported for the filing.

What the reported amounts show

Multiplying the specified 2,410 shares by $620.07 produces $1,494,368.70. That is $95,572.30 below the stated filing total of $1,589,941. These figures describe different levels of detail in the supplied summary: one identified sale and an aggregate covering two transactions.

The supplied material does not separately identify the share count, price or date for the other transaction. It therefore does not support assigning the remaining dollar amount to a particular number of shares or execution price. Nor should the entire filing total be described as proceeds from the specified 2,410 shares alone.

The source publication timestamp is September 29, 2026, at 20:13:22 UTC. That establishes when the supplied report was published; the summary does not independently provide a separate filing-submission timestamp.

What the disclosure can establish

The reported facts identify the seller, his executive role, the company, its ticker and the disclosed sales. They do not establish Troendle's reason for selling, his remaining ownership or whether the transactions represent a meaningful portion of his holdings.

Analysis: An executive sale provides information about that executive's transactions, but this limited summary cannot establish a view on Medpace's outlook. The absence of a reported 10b5-1 plan also does not, by itself, establish motive or improper conduct.

What to watch

The complete Form 4 would be the relevant document to check for both transaction entries, the filing date, post-sale holdings and any explanatory footnotes. Those details would help reconcile the aggregate proceeds with the individual sales.